Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Change in Acquisitions & Divestments (2016 - 2017)

Ocular Therapeutix (OCUL) has 3 years of Change in Acquisitions & Divestments data on record, last reported at $3.0 million in Q3 2017.

  • For Q3 2017, Change in Acquisitions & Divestments fell 79.57% year-over-year to $3.0 million; the TTM value through Dec 2017 reached $38.2 million, down 52.65%, while the annual FY2017 figure was $38.2 million, 52.65% down from the prior year.
  • Change in Acquisitions & Divestments reached $3.0 million in Q3 2017 per OCUL's latest filing, down from $22.7 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $30.0 million in Q3 2015 and bottomed at $3.0 million in Q3 2017.
  • Average Change in Acquisitions & Divestments over 3 years is $18.2 million, with a median of $16.0 million recorded in 2016.
  • Peak YoY movement for Change in Acquisitions & Divestments: rose 6.67% in 2016, then plummeted 79.57% in 2017.
  • A 3-year view of Change in Acquisitions & Divestments shows it stood at $15.0 million in 2015, then rose by 6.67% to $16.0 million in 2016, then tumbled by 81.25% to $3.0 million in 2017.
  • Per Business Quant database, its latest 3 readings for Change in Acquisitions & Divestments were $3.0 million in Q3 2017, $22.7 million in Q2 2017, and $12.5 million in Q1 2017.